reports
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarte...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 23,800 shares of Intellia’s common stock, with one-thi...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BXP BOSTON PROPERTIES INC.
AXTI AXT INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
ARGX ARGENX ADS
VTR VENTAS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
PEAK HEALTHPEAK PROPERTIES INC.
SMCI SUPER MICRO COMPUTER
BEAM INC.
STX BEAM THERAPEUTICS
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
GEMINI THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 ...
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patientsLonvo-z was well tolerated and c...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 33,600 shares of Intellia’s common stock, with one-thi...
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
AXTI AXT INC.
CDR CD PROJEKT S.A.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
ORIC INC.
AI ORIC PHARMACEUTICALS
STX C3.AI
GFS SEAGATE TECHNOLOGY HLDGS PLC
S GLOBALFOUNDRIES INC
JANX SENTINELONE INC
PEPG JANUX THERAPEUTICS INC
DBD PEPGEN INC
DIEBOLD NIXDORF INCORPORATED
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase...
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiranContinue to observe generally favorable safety and tolerability data in the f...
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Therapeutics Announces First Quarter 2025 Financial Results a...
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phas...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 69,600 shares of Intellia’s common stock, with one-thi...
- Wedbush Research
UDR UDR INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
GERN GERON CORP.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
CPT CAMDEN PROPERTY TRUST
CNK CINEMARK HOLDINGS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AVB AVALONBAY COMMUNITIES INC.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
VICI VICI PROPERTIES INC
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
RCUS ARCUS BIOSCIENCES
PEAK HEALTHPEAK PROPERTIES INC.
RVMD REVOLUTION MEDICINES
CRSR CORSAIR GAMING
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
RKT ROCKET COMPANIES
CSR CENTERSPACE
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
NTST NETSTREIT CORP
VIGL VIGIL NEUROSCIENCE INC
HR HEALTHCARE TRUST OF AMERICA INC.
SYRE SPYRE THERAPEUTICS INC.
BNL BROADSTONE NET LEASE INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
GERN GERON CORP.
BCRX BIOCRYST PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
RVMD REVOLUTION MEDICINES
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the c...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 8,400 shares of Intellia’s common stock, with one-...
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2...
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloid...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.